Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: Assessing all reasonable doses with innovative surface graph analysis

William Insull, Mark E. McGovern, Helmut Schrott, Paul Thompson, J. Robin Crouse, Franklin Zieve, John Corbelli

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Background: Combination therapy to improve the total lipid profile may achieve greater coronary risk reductions than lowering low-density lipoprotein cholesterol (LDL-C) alone. A new extended-release niacin (niacin ER)/lovastatin tablet substantially lowers LDL-C, triglyceride, and lipoprotein (a) levels and raises high-density lipoprotein cholesterol (HDL-C) level. We evaluated these serum lipid responses to niacin ER/lovastatin at all clinically reasonable doses. Methods: Men (n = 85) and women (n = 79) with type IIa or IIb primary hyperlipidemia after diet were randomized among 5 parallel treatment arms. Each arm had 5 sequential 4-week treatment periods: niacin ER (starting at 500 mg/d, increasing in 500-mg increments to 2500 mg/d); lovastatin (starting at 10 mg, increasing to 20 mg, then 40 mg/d); and 3 combinations arms, each with a constant lovastatin dose and escalating niacin ER doses. Results: For primary comparisons, mean LDL-C level reductions from baseline were greater with niacin ER/lovastatin (1500/20 mg) than with lovastatin (20 mg) (35% vs 22%, P<.001) and with niacin ER/lovastatin (2000/40 mg) than with lovastatin (40 mg) (46% vs 24%, P<.001). Each 500-mg increase in niacin ER, on average, decreased LDL-C levels an additional 4% and increased HDL-C levels 8%. The maximum recommended dose (2000/40 mg/d) increased HDL-C levels 29% and decreased LDL-C levels 46%, triglyceride levels 38%, and lipoprotein(a) levels 14%. All lipid responses were dose dependent and generally additive. Graphs of the dose-response relationships as 3-dimensional surfaces documented the strength and consistency of these responses. Conclusions: Niacin ER/lovastatin combination therapy substantially improves 4 major lipoprotein levels associated with atherosclerotic disease. Dose-response surfaces provide a practical guide for dose selection.

Original languageEnglish (US)
Pages (from-to)1121-1127
Number of pages7
JournalArchives of Internal Medicine
Volume164
Issue number10
DOIs
StatePublished - May 24 2004

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: Assessing all reasonable doses with innovative surface graph analysis'. Together they form a unique fingerprint.

Cite this